Braintree Laboratories
Trial Pipeline
Study 301: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy
NCT04446299
An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults
NCT02819310
A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris
NCT02604680
A Safety Study of 3 Different Bowel Cleansing Preparations
NCT01501513
BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
NCT00756548
BLI-800-301: BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
NCT00503607
Extended Use of Polyethyleneglycol3350 Laxative in Constipated Patients
NCT00153153
An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients
NCT00164125
Comparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications
NCT00153127
HalfLytely Bowel Prep System for Colonoscopy
NCT00164164
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 6 |
| Phase 4 | 3 |
Therapeutic Areas
What the Pipeline for Braintree Laboratories Shows
According to the ClinicalTrials.gov registry, Braintree Laboratories is linked to 10 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 10 are already marked complete, representing roughly 100% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Braintree Laboratories reports 9 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Braintree Laboratories is Colonoscopy with 4 linked trials, and 7 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.